Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Zollinger-Ellison Syndrome 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Stomach Ulcer 1Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia 1Leukemia, B-Cell 1Helicobacter Infections 1Gastritis, Atrophic 1Esophagitis, Peptic 1Endometrial Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Breast Neoplasms 1Barrett Esophagus 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × Lansoprazole × Clear all
NCT02625259 2018-01-08

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Takeda

Phase 1 Completed
54 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡